SLC5A2 and bacterial urinary tract infection: SGLT2 inhibitors were associated with a similar risk of UTI as a placebo [risk ratio 0.78 (95% CI 0.47–1.31), p = 0.35], and no groups showed a significant difference in the sub-group analysis.